靶向RAS介导的耐药在致癌基因驱动肺癌中的治疗策略
该研究通过组织和液体活检评估了590例致癌基因驱动肺癌患者对靶向治疗的耐药机制,发现RAS改变在约10%的耐药病例中起介导作用,且KRAS G12D富集而G12C罕见;在奥希替尼耐药的患者来源模型中,奥希替尼联合选择性KRAS G12D抑制剂zoldonrasib或泛RAS抑制剂daraxonrasib在体外和体内均显示出显著协同活性。
要点
- RAS改变介导约10%致癌基因驱动肺癌的靶向耐药。
- 奥希替尼耐药中KRAS G12D富集而G12C罕见。
- 临床前模型中奥希替尼联合新型RAS抑制剂显示协同活性。
核心结论
- RAS改变介导约10%致癌基因驱动肺癌对靶向药物的耐药。
- 与新型RAS抑制剂的合理联合在临床前模型中有效,为临床研究提供依据。
研究设计与样本
- 使用组织和液体活检评估590例致癌基因驱动肺癌患者的耐药机制。
- 建立两个奥希替尼耐药后获得性KRAS突变的患者来源模型进行体外和体内功能实验。
主要发现
- 在312例一线奥希替尼进展患者中,组织和液体活检在识别耐药机制方面具有主要互补作用。
- 312例中35例(11.2%)检出RAS改变,KRAS G12D富集(n=10),KRAS G12C罕见(n=1)。
- ALK阳性患者(n=148)中,劳拉替尼耐药时RAS改变较二代抑制剂更常见(14.7% vs 5%,P=0.0444)。
- MET、ROS1和RET驱动肺癌靶向治疗进展时,RAS改变检出率为7%-16%。
- 在两个奥希替尼耐药后获得性KRAS突变(分别为G12D和G12R)的患者来源模型中,奥希替尼联合zoldonrasib或daraxonrasib在体外和体内均显示显著协同活性。
临床怎么用
- 对致癌基因驱动肺癌靶向治疗进展患者,应结合组织和液体活检全面评估耐药机制。
- RAS改变是潜在的耐药靶点,联合新型RAS抑制剂值得临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the dramatic activity of next-generation targeted therapies, most patients with oncogene-driven lung cancers eventually relapse. Novel inhibitors are particularly active against on-target resistance, fostering the emergence of off-target resistance mechanisms. The current clinical development of RAS inhibitors hints at their potential role in overcoming off-target resistance mediated by RAS alterations. PATIENTS AND METHODS: Using tissue and liquid biopsies, we assessed resistance mechanisms to first-line osimertinib in patients with epidermal growth factor receptor-mutant lung cancer and to ALK, MET, ROS1, and RET inhibitors, for a total of 590 patients. We established two patient-derived models with acquired KRAS mutations obtained at osimertinib progression, enabling in vitro and in vivo functional experiments. RESULTS: Among 312 patients progressing on first-line osimertinib, we observed a major complementary role of tissue and liquid biopsies in identifying resistance mechanisms. We identified RAS alterations in 35 of 312 patients (11.2%), with an enrichment in KRAS G12D (n = 10) and a paucity of KRAS G12C (n = 1) mutations. In patients with ALK-positive disease (n = 148), RAS alterations were more common at resistance to lorlatinib compared with second-generation inhibitors (14.7% versus 5%, P = 0.0444). Across MET-, ROS1-, and RET-driven lung cancers at progression to targeted agents, RAS alterations were detected in 7%-16% of the cases. In the two patient-derived models established at osimertinib resistance with acquired KRAS mutations (G12D and G12R, respectively), we tested the combinatorial effect of osimertinib with either the selective KRAS G12D inhibitor zoldonrasib or the pan-RAS inhibitor daraxonrasib. Both combinations demonstrated marked synergistic activity in vitro and in vivo. CONCLUSIONS: RAS alterations mediate resistance to targeted agents in ∼10% of oncogene-driven lung cancer. Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.
引用
- Facchinetti F, Friboulet L, Liao L, et al. Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer. Ann Oncol. 2026. PMID: 42612796. doi:10.1016/j.annonc.2026.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。